ES2175663T3 - Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. - Google Patents

Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.

Info

Publication number
ES2175663T3
ES2175663T3 ES98904121T ES98904121T ES2175663T3 ES 2175663 T3 ES2175663 T3 ES 2175663T3 ES 98904121 T ES98904121 T ES 98904121T ES 98904121 T ES98904121 T ES 98904121T ES 2175663 T3 ES2175663 T3 ES 2175663T3
Authority
ES
Spain
Prior art keywords
treatment
oral administration
miltephosine
leshmaniasis
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98904121T
Other languages
English (en)
Inventor
Jurgen Engel
Werner Sarlikiotis
Thomas Klenner
Peter Hilgard
Dieter Sauerbier
Eckhard Milsmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Application granted granted Critical
Publication of ES2175663T3 publication Critical patent/ES2175663T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Utilización de miltefosina para la preparación de un medicamento para el tratamiento de la leishmaniasis en la especie humana por administración oral, por la que se administra oralmente una dosis diaria total en el intervalo de 10 a 250 mg del i.a. (ingrediente activo) miltefosina durante un período de tiempo de 2 a 6 semanas.
ES98904121T 1998-01-22 1998-01-22 Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. Expired - Lifetime ES2175663T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (1)

Publication Number Publication Date
ES2175663T3 true ES2175663T3 (es) 2002-11-16

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98904121T Expired - Lifetime ES2175663T3 (es) 1998-01-22 1998-01-22 Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.

Country Status (24)

Country Link
US (1) US6544551B1 (es)
EP (1) EP1051159B1 (es)
JP (1) JP2002501015A (es)
KR (1) KR100517399B1 (es)
CN (1) CN100413492C (es)
AT (1) ATE215817T1 (es)
AU (1) AU756805B2 (es)
BR (1) BR9814772A (es)
CA (1) CA2318260C (es)
CZ (1) CZ299229B6 (es)
DE (1) DE69804865T2 (es)
DK (1) DK1051159T3 (es)
ES (1) ES2175663T3 (es)
HU (1) HUP0004363A3 (es)
IL (1) IL136196A (es)
NO (1) NO20003674D0 (es)
NZ (1) NZ505648A (es)
PL (1) PL189654B1 (es)
PT (1) PT1051159E (es)
SI (1) SI1051159T1 (es)
SK (1) SK284839B6 (es)
TR (1) TR200001717T2 (es)
UA (1) UA68372C2 (es)
WO (1) WO1999037289A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
WO2003090757A1 (en) * 2002-04-26 2003-11-06 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
JP2005535688A (ja) 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
CA2526586C (en) 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
BR112013012652A2 (pt) 2010-11-22 2016-09-06 Dafra Pharma Res & Dev Bvba forma de dosagem sólida de oleil fosfocolina para administração oral, forma de dosagem sólida, e método para a preparação de uma forma de dosagem sólida
AU2012272642B2 (en) 2011-06-24 2017-09-07 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
WO2014166941A1 (en) * 2013-04-08 2014-10-16 Academisch Medisch Centrum Miltefosin or perifosin for use in the treatment of ibd
WO2016042372A1 (en) 2014-09-17 2016-03-24 Steer Engineering Private Limited Effervescent composition and method of making it
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
WO2017098481A1 (en) 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
PL3965739T3 (pl) * 2019-04-12 2025-01-13 Oblita Therapeutics Bvba Postacie dawkowane będące tabletkami oleilofosfocholiny

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
IE59777B1 (en) * 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicaments
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Also Published As

Publication number Publication date
SI1051159T1 (en) 2002-10-31
PT1051159E (pt) 2002-09-30
HUP0004363A2 (hu) 2001-04-28
CA2318260C (en) 2006-11-21
CN100413492C (zh) 2008-08-27
CZ20002596A3 (cs) 2000-10-11
EP1051159A1 (en) 2000-11-15
EP1051159B1 (en) 2002-04-10
NO20003674L (no) 2000-07-18
NZ505648A (en) 2002-10-25
KR20010034311A (ko) 2001-04-25
HUP0004363A3 (en) 2002-12-28
JP2002501015A (ja) 2002-01-15
IL136196A (en) 2004-07-25
WO1999037289A1 (en) 1999-07-29
SK9862000A3 (en) 2000-11-07
DE69804865T2 (de) 2002-11-07
CN1283111A (zh) 2001-02-07
DK1051159T3 (da) 2002-08-05
SK284839B6 (sk) 2005-12-01
TR200001717T2 (tr) 2000-11-21
PL189654B1 (pl) 2005-09-30
US6544551B1 (en) 2003-04-08
ATE215817T1 (de) 2002-04-15
PL342838A1 (en) 2001-07-16
BR9814772A (pt) 2000-10-24
DE69804865D1 (de) 2002-05-16
CA2318260A1 (en) 1999-07-29
CZ299229B6 (cs) 2008-05-21
IL136196A0 (en) 2001-05-20
AU756805B2 (en) 2003-01-23
KR100517399B1 (ko) 2005-09-28
AU6212198A (en) 1999-08-09
UA68372C2 (en) 2004-08-16
NO20003674D0 (no) 2000-07-18

Similar Documents

Publication Publication Date Title
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CR6458A (es) Composiciones de valdecoxib
BR0015188A (pt) Composições farmacêuticas
KR960700708A (ko) 3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman)
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
CZ289643B6 (cs) Lék pro léčbu bolesti v krku obsahující flurbiprofen
EP1444984B1 (en) Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
NO20055880L (no) Memantin orale doseringsformer
SE9901573D0 (sv) New compounds
BR0114100A (pt) Formulações de liberação controlada para administração oral
ES2171440T3 (es) Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal.
KR970025615A (ko) 암 전이 억제제
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
MXPA03003994A (es) Composiciones de metformina de liberacion controlada.
BR0014593A (pt) Unidade de dosagem para administração peroral
ES2078838A1 (es) Procedimiento para preparar una composicion a base de clozapina.
AR042153A1 (es) Uso de los compuestos 2,5- dihidroxibencenosulfonicos para la fabricacion de un medicamento
AR030551A1 (es) Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1051159

Country of ref document: ES